Recent developments in the early diagnosis and management of multiple sclerosis

Journal of Neuroscience Nursing

Volumn 42, Issue 6, 2010, Pages 342-353

  Ross, Amy Perrin ^a   Thrower, Ben W ^b  

^a Department of Neurology   (United States)

^b Shepherd MS Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR;

ARTICLE; CLINICAL COMPETENCE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EVOKED VISUAL RESPONSE; HEALTH PERSONNEL ATTITUDE; HUMAN; MULTIPLE SCLEROSIS; NEEDS ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NURSE; NURSE ATTITUDE; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE;

ATTITUDE OF HEALTH PERSONNEL; CLINICAL COMPETENCE; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; EVOKED POTENTIALS, VISUAL; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEEDS ASSESSMENT; NURSE'S ROLE; NURSES; PATIENT CARE TEAM; PATIENT SELECTION; RECURRENCE;

EID: 78651488932     PISSN: 08880395     EISSN: None     Source Type: Journal    
DOI: 10.1097/JNN.0b013e3181f8a5d0     Document Type: Article

References (64)

1. Bakshi, R., Thompson, A. J., Rocca, M. A., Pelletier, D., Dousset, V., Barkhof, F., et al. (2008). MRI in multiple sclerosis: Current status and future prospects. Lancet Neurology, 7(7), 615-625.
2. Barkhof, F., Filippi, M., Miller, D. H., Scheltens, P., Campi, A., Polman, C. H., et al. (1997). Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain, 120(Pt. 11), 2059-2069.
3. Bielekova, B., Howard, T., Packer, A. N., Richert, N., Blevins, G., Ohayon, J., et al. (2009). Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Archives of Neurology, 66(4), 483-489.
4. Brandes, D. W., Callender, T., Lathi, E., & O'Leary, S. O. (2009). A review of disease modifying therapies for MS: Maximizing adherence and minimizing adverse events. Current Medical Research and Opinion, 25(1), 77-92.
5. Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002). A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. New England Journal of Medicine, 346(3), 158-164.
6. Brinkmann, V., Cyster, J. G., & Hla, T. (2004). FT-720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. American Journal of Transplantation, 4(7), 1019-1025.
7. Buhse, M. (2006). Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis. Journal of Neuroscience Nursing, 38(4), 222-226.
8. Caon, C. (2007). Evolution of MRI in MS: Conventional imaging techniques. International Journal of MS Care, 9(Suppl. 3), 1-5.
9. Charil, A., Yousry, T. A., Rovaris, M., Barkhof, F., De Stefano, N., Fazekas, F., et al. (2006). MRI and the diagnosis of multiple sclerosis: Expanding the concept of Bno better explanation.[Lancet Neurology, 5, 841-852.
10. Clerico, M., Barbero, P., Contessa, G., Ferrero, C., & Durelli, L. (2007). Adherence to interferon-beta treatment and results of switching therapy. Journal of the Neurological Sciences, 229, 104-108.
11. Cohen, J. A., Barkhof, F., Comi, G., Hartung, H. P., Katri, B. O., Montalban, X., et al. (2010). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New England Journal of Medicine, 362(5), 402-415.
12. Coles, A. J., Compston, D. A. S., Selmaj, K. W., Lake, S. L., Moran, S., Margolin, D. H., et al. (2008). Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New England Journal of Medicine, 359(17), 1786-1801.
13. Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernandez, O., et al. (2001). Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomized study. Lancet, 357, 1576-1582.
14. Comi, G.,Martinelli, V., Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., et al. (2009). Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet, 374(9700), 1503-1511.
15. Comi, G., Pulizzi, A., Rovaris, M., Abramsky, O., Arbizu, T., Boiko, A., et al. (2008). Effect of laquinimod on MRImonitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, 371(9630), 2085-2092.
16. Consortium of Multiple Sclerosis Centers. (2009). MRI protocol for the diagnosis and follow-up of MS. Proposed 2009 revised guidelines. Retrieved from http://www.mscare.org/cmsc/images/pdf/mriprotocol2009.pdf
17. Costello, K., Kennedy, P., & Scanzillo, J. (2008). Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence long term. Medscape Journal of Medicine, 10(9), 225.
18. Cox, D., & Stone, J. (2006). Managing self-injection difficulties in patients with relapsingYremitting multiple sclerosis. Journal of Neuroscience Nursing, 38, 167-171.
19. Coyle, P., Leist, T., Comi, G., Cree, B., Freedman, M., Orejudos, A., et al. (2009). Study design of the ORACLE multiple sclerosis study: Cladribine tablets in early multiple acerosis. International Journal of MS Care, 11(Suppl. 2), 84.
20. Cramer, J. A., Cuffel, B. J., Divan, B., Al-Sabbagh, A., & Glassman, M. (2006). Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurologica Scandinavica, 113, 156-162.
21. Edwards, R. G., Barlow, J. H., & Turner, A. P. (2008). Experiences of diagnosis and treatment among people with multiple sclerosis. Journal of Evaluation in Clinical Practice, 14, 460-464.
22. Giacomini, P. S., Darlington, P. J., & Bar-Or, A. (2009). Emerging multiple sclerosis disease-modifying therapies. Current Opinion in Neurology, 22(3), 226-232.
23. Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Soelberg-Sorensen, P., et al. (2010). A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New England Journal of Medicine, 362(5), 416-426.
24. Goodin, D. S., Frohman, E. M., Garmany, G. P., Halper, J., Likosky, W. H., Lublin, F. D., et al. (2002). Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology, 58(2), 169-178.
25. Greenberg, B. M., & Calabresi, P. A. (2008). Future research directions in multiple sclerosis therapies. Seminars in Neurology, 28, 121-128.
26. Hakiki, B., Goretti, B., Portaccio, E., Zipoli, V., & Amato, M. P. (2008). 'Subclinical MS': Follow-up of four cases. European Journal of Neurology, 15, 858-861.
27. Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., et al. (2008). B-cell depletion with rituximab in relapsingYremitting multiple sclerosis. New England Journal of Medicine, 358(7), 676-688. (Pubitemid 351240747)
28. Hawker, K. (2008). B-cell-targeted treatment for multiple sclerosis: Mechanism of action and clinical data. Current Opinion in Neurology, 21(Suppl. 1), S19-S25.
29. Jacobs, L., Beck, R., Simon, J., Kinkel, R., Brownscheidle, C., Murray, T., et al. (2000). Intramuscular Interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. New England Journal of Medicine, 343, 898-904.
30. Jolly, H., Simpson, K., Bishop, B., Hunter, H., Newell, C., Denney, D., et al. (2008). Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. Journal of Neuroscience Nursing, 40(4), 232-239.
31. Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., et al. (2006). Oral fingolimod (FT-720) for relapsing multiple sclerosis. New England Journal of Medicine, 355(11), 1124-1140.
32. Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H. P., Miller, D. H., et al. (2009). Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology, 8(11), 987-997.
33. Kappos, L., Gold, R., Miller, D. H., MacManus, D. G., Havrdova, E., Limmroth, V., et al. (2008). Efficacy and safety of oral fumarate in patients with relapsingYremitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, 372(9648), 1463-1472.
34. Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D., et al. (2006). Treatment with interferon beta-1b delays conversion to clinically definite andMcDonald MS in patients with clinically isolated syndromes. Neurology, 67, 1242-1249.
35. Kappos, L., Radue, E. W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., et al. (2010). A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine, 362(5), 287-401.
36. Khan, F., Turner-Stokes, L., Ng, L., & Kilpatrick, T. (2007). Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database of Systematic Reviews, 18(2), CD006036.
37. Khan, O. (2007). Introduction to nonconventional sequences and imaging. International Journal of MS Care, 9(Suppl. 3), 6-9.
38. Kinkel, R. P., Dontchev, M., Tanner, J. P., Kollman, C., Simon, J., O'Connor, P. W., et al. (2009). CHAMPIONS: 10-year follow-up after a clinically isolated syndrome in patients at high risk for developing multiple sclerosis. Poster presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 9-12, 2009, Desseldorf, Germany, P446.
39. Langer-Gould, A., Moses, H. H., & Murray, T. J. (2004). Strategies for managing the side effects of treatments for multiple sclerosis. Neurology, 63(11 Suppl. 5), S35-S41.
40. Leist, T. P., & Vermersch, P. (2007). The potential role for cladribine in the treatment of multiple sclerosis: Clinical experience and development of an oral tablet formulation. Current Medical Research and Opinion, 23(11), 2667-2676.
41. MacLean, R. (2004). The challenge of managing patients with multiple sclerosis. Nursing Times, 100(4), 42-44.
42. Marrie, R. A., Horwitz, R., Cutter, G., Tyry, T., Campagnolo, D., & Vollmer, T. (2009). Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology, 72(2), 117-124.
43. Mastronardo,G.,Rocca, M. A., Iannucci, G., Pereira, C., & Filippi, M. (1999). A longitudinal MR study of the presymptomatic phase in a patient with clinically definite multiple sclerosis. AJNR. American Journal of Neuroradiology, 20, 1268-1272.
44. McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H. P., Lublin, F. D., et al. (2001). Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology, 50(1), 121-127.
45. Menge, T., Weber, M. S., Hemmer, B., Kieseier, B. C., von Budingen, H. C., Warnke, C., et al. (2008). Diseasemodifying agents for multiple sclerosis: Recent advances and future prospects. Drugs, 68(17), 2445-2468.
46. Miller, D. H., Weinshenker, B. G., Filippi, M., Banwell, B. L., Cohen, J. A., Freedman, M. S., et al. (2008). Differential diagnosis of suspected multiple sclerosis: A consensus approach. Multiple Sclerosis, 14, 1157-1174.
47. Minneboo, A., Barkhof, F., Polman, C. H., Uitdehaag, B. M., Knol, D. L., & Castelijns, J. A. (2004). Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Archives of Neurology, 61(2), 217-221.
48. National Clinical Advisory Board of the National Multiple Sclerosis Society. (2007). Disease management consensus statement. Retrieved March 3, 2009, from http://www.nationalmssociety.org/about-multiplesclerosis/treatments/ download.aspx?id=8
49. Neema, M., Stankiewicz, J., Arora, A., Guss, Z. D., & Bakshi, R. (2007). MRI in multiple sclerosis; what's inside the toolbox? Neurotherapeutics, 4, 602-617.
50. O'Connor, P., Comi, G., Montalban, X., Antel, J., Radue, E. W., de Vera, A., et al. (2009). Oral fingolimod (FT-720) in multiple sclerosis: Two-year results of a phase II extension study. Neurology, 72(1), 73-79.
51. O'Connor, P.W.,Li, D., Freedman, M. S., Bar-Or, A., Rice, G. P., Confavreux, C., et al. (2006). A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology, 66(6), 894-900.
52. Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., et al. (2009). Incidental MRI anomalies suggestive of multiple sclerosis. Neurology, 72, 800-805.
53. Perrin Ross, A. (2008). Tolerability, adherence, and patient outcomes. Neurology, 71(Suppl. 3), S21-S23.
54. Perrin Ross, A., Singer, B., Kresa-Reahl, K., Mikol, D., Al-Sabbagh, A., Bennett, R., et al. (2007). Reduction in injectionsite reactions with hydrocortisone, witch hazel, or moisturizing lotion after subcutaneous interferon beta 1a treatment for multiple sclerosis. Multiple Sclerosis, 13, S134-S135.
55. Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the BMcDonald Criteria[. Annals of Neurology, 58(6), 840-846.
56. Rose, J. W., Burns, J. B., Bjorklund, J., Klein, J., Watt, H. E., & Carlson, N. G. (2007). Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology, 69(8), 785-789.
57. Rovira, A., & León, A. (2008). MR in the diagnosis and monitoring of multiple sclerosis. European Journal of Radiology, 67, 409-414.
58. Simon, J. H., Li, D., Traboulsee, A., Coyle, P. K., Arnold, D. L., Barkhof, F., Frank, J. A., et al. (2006). Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers Consensus Guidelines. AJNR. American Journal of Neuroradiology, 27, 455-461.
59. Sipe, J. C. (2005). Cladribine for multiple sclerosis: Review and current status. Expert Review of Neurotherapeutics, 5(6), 721-727.
60. Solari, A., Acquarone, N., Pucci, E., Martinelli, V., Marrosu, M. G., Trojano, M., et al. (2007). Communicating the diagnosis of multiple sclerosis: A qualitative study. Multiple Sclerosis, 13, 763-769.
61. Tan, I. L., Lycklama à Nijeholt, G. J., Polman, C. H., Adèr, H. J., & Barkhof, F. (2000). Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. Multiple Sclerosis, 6(2), 99-104.
62. Tintoré, M., Rovira, A., Martínez, M. J., Rio, J., Díaz-Villoslada, P., Brieva, L., et al. (2000). Isolated demyelinating syndromes: Comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR. American Journal of Neuroradiology, 21, 702-706.
63. Tintoré,M., Rovira, A., Rio, J., Nos, C., Grivé, E., Téllez, N., et al. (2006). Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology, 67(6), 968-972.
64. Wattjes, M. P., Harzheim, M., Kuhl, C. K., Gieseke, J., Schmidt, S., Klotz, L., et al. (2006). Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic MR imaging criteria for multiple sclerosis? AJNR. American Journal of Neuroradiology, 7(8), 1794-1798.